Axsome Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Axsome Therapeutics heeft een totaal eigen vermogen van $102.9M en een totale schuld van $179.3M, wat de schuld-eigenvermogensverhouding op 174.4% brengt. De totale activa en totale passiva bedragen respectievelijk $548.2M en $445.4M.
Belangrijke informatie
174.4%
Verhouding schuld/eigen vermogen
US$179.33m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$315.66m |
| Aandelen | US$102.85m |
| Totaal verplichtingen | US$445.37m |
| Totaal activa | US$548.23m |
Recente financiële gezondheidsupdates
Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Recent updates
Axsome: AXS-07 And Its Upcoming Second PDUFA
Oct 15Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $463.0M ) AXSM } overtreffen de korte termijn passiva ( $186.6M ).
Langlopende schulden: De kortetermijnactiva AXSM ( $463.0M ) overtreffen de langetermijnschulden ( $258.8M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: AXSM heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van AXSM is de afgelopen 5 jaar gestegen van 80.6% naar 174.4%.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: AXSM heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.
Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of AXSM voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.